Merseyside Inter Agency Drug Misuse Database

St Helens DAT

Quarter 4 2007/08

**Lloyd Baron, Martin Chandler,
Jim McVeigh**

www.cph.org.uk/iad

Contacts:
Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531
m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521
L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

National Drug Treatment Monitoring System (NDTMS)   13

Connexions   16

Combined Datasets   18

Cross Matched Datasets   19

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)
Quarter 4 (2007/08)

Introduction
Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	77	81.9
Female	17	18.1
Age Group		
Under 18	0	0.0
18-19	10	10.6
20-24	12	12.8
25-29	23	24.5
30-34	19	20.2
35-39	15	16.0
40-44	12	12.8
45+	3	3.2
Total	*94*	*100*

Table 2: Year to Date, by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	*n*	*%*
Under 18	0	0.0	0	0.0	*0*	*0.0*
18-19	21	7.8	4	8.0	*25*	*7.8*
20-24	53	19.6	8	16.0	*61*	*19.1*
25-29	70	25.9	16	32.0	*86*	*26.9*
30-34	53	19.6	7	14.0	*60*	*18.8*
35-39	34	12.6	7	14.0	*41*	*12.8*
40-44	30	11.1	7	14.0	*37*	*11.6*
45+	9	3.3	1	2.0	*10*	*3.1*
Total	*270*	*100*	*50*	*100*	*320*	*100*

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	1	0
Benzodiazepines	5	3
Cannabis	9	2
Crack	16	5
Cocaine	11	14
Ecstasy	0	0
Heroin	42	7
Methadone	5	2
Subutex	1	0
Other	2	0

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES
Quarter 4 (2007/08)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	155	92.8
Female	12	7.2
Total	167	100
All Clients		
Male	382	90.5
Female	40	9.5
Total	422	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	113	90.4
Female	12	9.6
Total	125	100
All Clients		
Male	271	87.1
Female	40	12.9
Total	311	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	1.2	2	>1
18-19	5	3.0	8	1.9
20-24	29	17.4	52	12.3
25-29	30	18.0	80	19.0
30-34	32	19.2	81	19.2
35-39	36	21.6	92	21.8
40-44	24	14.4	74	17.5
45+	9	5.4	33	7.8
Total	*167*	*100*	*422*	*100*

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	1.6	2	>1
18-19	3	2.4	3	1.0
20-24	12	9.6	22	7.1
25-29	18	14.4	51	16.4
30-34	29	23.2	67	21.5
35-39	31	24.8	76	24.4
40-44	22	17.6	61	19.6
45+	8	6.4	29	9.3
Total	*125*	*100*	*311*	*100*

Table 8: Gender by Age Group of Individuals

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	2	>1	0	0.0
18-19	8	2.1	0	0.0
20-24	46	12.0	6	15.0
25-29	72	18.8	8	20.0
30-34	69	18.1	12	30.0
35-39	85	22.3	7	17.5
40-44	69	18.1	5	12.5
45+	31	8.1	2	5.0
Total	*382*	*100*	*40*	*100*

Table 9: Gender by Age Group: Steroid Users omitted

	Gender			
	Male		Female	
Age Group	n	%	n	%
Under 18	2	>1	0	0.0
18-19	3	1.1	0	0.0
20-24	16	5.9	6	15.0
25-29	43	15.9	8	20.0
30-34	55	20.3	12	30.0
35-39	69	25.5	7	17.5
40-44	56	20.7	5	12.5
45+	27	10.0	2	5.0
Total	*271*	*100*	*40*	*100*

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	<1	0	0.0	2	<1
18-19	13	2.3	0	0.0	13	2.1
20-24	70	12.4	7	12.3	77	12.4
25-29	113	20.0	14	24.6	127	20.4
30-34	110	19.5	16	28.1	126	20.3
35-39	124	21.9	10	17.5	134	21.5
40-44	84	14.9	6	10.5	90	14.5
45+	49	8.7	4	7.0	53	8.5
Total	565	100	57	100	622	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	<1	0	0.0	2	<1
18-19	3	<1	0	0.0	3	<1
20-24	18	4.8	7	12.5	25	5.8
25-29	60	16.0	14	25.0	74	17.2
30-34	86	22.9	16	28.6	102	23.7
35-39	95	25.3	9	16.1	104	24.1
40-44	66	17.6	6	10.7	72	16.7
45+	45	12.0	4	7.1	49	11.4
Total	375	100	56	100	431	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	10	6.5	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	67	43.2	10	83.3
Methadone	12	7.7	1	8.3
Steroids	42	27.1	0	0.0
Other	24	15.4	1	8.3
Total	*155*	*100*	*12*	*100*

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta-mine		Benzodi-azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18-19	-	-	-	-	-	-	-	-	2	3.0	-	-	2	5.0
20-24	-	-	-	-	-	-	-	-	5	6.0	-	-	17	40.0
25-29	2	20.0	-	-	-	-	-	-	11	14.0	-	-	12	29.0
30-34	-	-	-	-	-	-	-	-	25	32.0	-	-	3	7.0
35-39	3	30.0	-	-	-	-	-	-	20	26.0	6	46.0	5	12.0
40-44	4	40.0	-	-	-	-	-	-	10	13.0	5	37.0	2	5.0
45+	1	10.0	-	-	-	-	-	-	4	6.0	2	15.0	1	2.0
*Total**	*10*	*100*	*-*	*-*	*-*	*-*	*-*	*-*	*77*	*100*	*13*	*100*	*42*	*100*

* % Totals are by Drug, not Age Group

PHARMACY SYRINGE EXCHANGE

Table 14: Individuals by Gender

New Clients	n	%
Male	68	94.4
Female	4	5.6
Total	72	100
All Clients		
Male	132	86.3
Female	21	13.7
Total	153	100

Table 15: Individuals by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	4	5.6	4	2.6
20-24	7	9.7	12	7.8
25-29	8	11.1	21	13.7
30-34	21	29.2	47	30.7
35-39	13	18.1	33	21.6
40-44	12	16.7	25	16.3
45+	7	9.7	11	7.2
Total	72	100	153	100

Table 16: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	7	2.7	0	0.0	7	2.3
20-24	20	7.6	4	9.5	24	7.9
25-29	41	15.6	12	28.6	53	17.4
30-34	76	29.0	12	28.6	88	28.9
35-39	53	20.2	6	14.3	59	19.4
40-44	40	15.3	4	9.5	44	14.5
45+	25	9.5	4	9.5	29	9.5
Total	262	100	42	100	304	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 17: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	216	93.5
Female	15	6.5
Total	*231*	*100*
All Clients		
Male	473	90.1
Female	52	9.9
Total	*525*	*100*

Table 18: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted

New Clients	n	%
Male	173	92.0
Female	15	8.0
Total	*188*	*100*
All Clients		
Male	360	87.4
Female	52	12.6
Total	*412*	*100*

Table 19: Individuals in Syringe Exchange, by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	2	>1	2	>1
18-19	9	3.9	12	2.3
20-24	36	15.6	61	11.6
25-29	37	16.0	93	17.7
30-34	53	22.9	116	22.1
35-39	44	19.0	108	20.6
40-44	35	15.2	91	17.3
45+	15	6.5	42	8.0
Total	*231*	*100*	*525*	*100*

Table 20: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	1.1	2	>1
18-19	6	3.2	6	1.5
20-24	19	10.1	31	7.5
25-29	25	13.3	64	15.5
30-34	50	26.6	102	24.8
35-39	39	20.7	92	22.3
40-44	33	17.6	78	18.9
45+	14	7.4	37	9.0
Total	*188*	*100*	*412*	*100*

Table 21: Year to Date, by Gender & Age Group

Age Group	Gender				*Total in Age Group*	
	Male		Female			
	n	%	n	%	*n*	*%*
Under 18	2	>1	0	0.0	*2*	*>1*
18-19	20	2.7	0	0.0	*20*	*2.4*
20-24	86	11.7	9	11.1	*95*	*11.6*
25-29	140	19.0	19	23.5	*159*	*19.5*
30-34	158	21.5	24	29.6	*182*	*22.3*
35-39	151	20.5	13	16.0	*164*	*20.1*
40-44	110	14.9	8	9.9	*118*	*14.4*
45+	69	9.4	8	9.9	*77*	*9.4*
Total	*736*	*100*	*81*	*100*	*817*	*100*

Table 22: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	YTD
Barrels	18,737	2,474	21,211	72,376

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2007/08)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 23: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	130	81.8
Female	29	18.2
Total	159	100
All Clients		
Male	833	76.6
Female	255	23.4
Total	1088	100

Table 24: Year to Date, by Gender

New Clients	n	%
Male	368	78.1
Female	103	21.9
Total	471	100
All Clients		
Male	907	76.7
Female	276	23.3
Total	1183	100

Table 25: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	18	11.3	66	6.1
18-19	6	3.7	31	2.8
20-24	10	6.2	84	7.7
25-29	35	22.0	178	16.3
30-34	38	23.9	232	21.3
35-39	33	20.7	244	22.4
40-44	18	11.3	137	12.6
45+	1	>1	116	10.7
Total	159	100	1088	100

Table 26: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	47	10.0	91	7.7
18-19	17	3.6	34	2.9
20-24	52	11.0	144	12.2
25-29	98	20.8	246	20.8
30-34	101	21.4	263	22.2
35-39	97	20.6	222	18.8
40-44	39	8.3	109	9.2
45+	20	4.2	74	6.3
Total	471	100	1183	100

Table 27: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	157	98.74	1073	98.6
White Irish	1	>1	3	>1
Other White	1	>1	5	>1
White & Black Caribbean	0	0.0	2	>1
Other Mixed	0	0.0	1	>1
Other	0	0.0	3	>1
Unknown	0	0.0	1	>1
Total	*159*	*100*	*1088*	*100*

Table 28: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	88	55.3	692	63.6
Methadone	6	3.7	64	5.8
Other Opiates	2	1.2	23	2.1
Benzodiazepine	1	>1	5	>1
Amphetamines	5	3.1	31	2.8
Cocaine	21	13.2	123	11.3
Crack	5	3.1	25	2.3
Ecstasy	3	1.8	10	>1
Cannabis	22	13.8	96	8.8
Other/Unknown	6	4.1	19	2.0
Total	*159*	*100*	*1088*	*100*

CONNEXIONS
Quarter 4 (2007/08)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 29: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	24	60.0
Female	16	40.0
Total	40	100

Table 30: Year to Date, by Gender

Gender	n	%
Male	34	61.8
Female	21	38.2
Total	55	100

Table 31: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	5	12.5
17	14	35.0
18	12	30.0
19	9	22.5
Total	40	100.0

Table 32: Year to Date, by Age

Age Group	n	%
16	10	18.2
17	16	29.1
18	12	21.8
19	17	30.9
Total	55	100

Table 33: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	14	35.0
Drugs	26	65.0
Total	40	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 34: Year to Date, by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	21	38.2
Drugs	34	61.8
Total	55	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS
Quarter 4 (2007/08)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 35: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1216	80.6
Female	292	19.4
Age Group		
Under 18	101	6.7
18-19	67	4.4
20-24	186	12.3
25-29	279	18.5
30-34	323	21.4
35-39	274	18.2
40-44	177	11.7
45+	101	6.7
Total	*1508*	*100*

Table 36: Year to Date, by Gender and Age Group

	Gender					
	Male		**Female**		*Total in Age Group*	
Age Group	**n**	**%**	**n**	**%**	*n*	*%*
Under 18	71	4.3	25	7.0	*96*	*4.8*
18-19	86	5.3	15	4.2	*101*	*5.1*
20-24	194	11.8	46	12.9	*240*	*12.0*
25-29	286	17.5	67	18.8	*353*	*17.7*
30-34	315	19.2	79	22.1	*394*	*19.7*
35-39	322	19.7	65	18.2	*387*	*19.4*
40-44	212	12.9	34	9.5	*246*	*12.3*
45+	152	9.3	26	7.3	*178*	*8.9*
Total	*1638*	*100*	*357*	*100*	*1995*	*100*

CROSS-MATCHED DATASETS
Quarter 4 (2007/08)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

AGENCY
(311)

142 Male
28 Female

NDTMS
(1088)

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

PHARMACY
(153)

46 Male
17 Female

NDTMS
(1088)